Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company focused on sepsis and septic shock, has released its financial results for the second quarter ended June 30, 2026, alongside a corporate update highlighting a key regulatory milestone. The company completed and received FDA filing acceptance for its Premarket Approval application for Toraymyxin™ (PMX), its hemoperfusion device targeting endotoxic septic shock. Separately, 12-month follow-up data from the Tigris trial showed that the survival benefit observed earlier in the trial persisted through one year, a development the company described as strengthening the totality of clinical evidence supporting PMX.
Key Points
- Spectral Medical Inc. (TSX: EDT) is a Toronto-based late-stage theranostic company
- The FDA formally accepted Spectral's PMA application for PMX on June 25, 2026, initiating substantive review
- Q2 2026 revenue was $621,000, down 24% from $813,000 in Q2 2025; the company recorded a net gain of $331,000 for the quarter
- Investors may be watching the FDA review timeline, anticipated pre-approval inspections, and the company's ongoing financing evaluation
FDA PMA Filing Acceptance Marks Regulatory Inflection Point for PMX
Spectral submitted its PMA application to the FDA on May 28, 2026, with the agency completing its filing review and formally accepting the application on June 25, 2026. The submission included final 12-month follow-up data from the Tigris trial. The company states it is now actively supporting the FDA review process and preparing for anticipated pre-approval inspections at both Spectral and device manufacturer Toray. Commercialisation planning is continuing alongside exclusive U.S. and Canadian distribution partner Vantive, with Vantive also intending to submit a 510(k) application for its PrisMax system, expected to serve as the primary ICU platform for PMX treatment.
Tigris Trial 12-Month Data Shows Persistent Survival Benefit for PMX-Treated Patients
Announced on June 4, 2026, the 12-month follow-up results from the Tigris trial were reported with 100% patient follow-up. Mortality at 12 months was 52.8% in PMX-treated patients compared to 66.7% in patients receiving standard of care, representing an absolute mortality reduction of 13.9% and a number needed to treat of 7.2. Initial Bayesian analyses based solely on the randomised Tigris trial demonstrated a 95.9% probability of benefit at 12 months. The release states that the survival benefit observed at 28 and 90 days persisted through one year, with consistency across multiple clinically meaningful endpoints.
Q2 Revenue Declines as Clinical Wind-Down Reduces Operating Costs Sharply
Q2 2026 revenue of $621,000 declined 24% year-over-year, attributed primarily to lower reagent sales and reduced service revenue following conclusion of the Vantive PrisMax sub-study in May 2026. Operating expenses for the quarter fell 98% to $62,000 from $2,514,000 in Q2 2025, driven largely by non-cash fair value adjustments on derivative liabilities and the winding down of clinical site activities. The company reported a net gain of $331,000 for Q2 2026 versus a loss of $1,933,000 in the prior year period. For the six months ended June 30, 2026, the net loss narrowed to $2,607,000 from $14,539,000 in the same period last year.
Vantive Completes US$2.0 Million Tranche D Funding Under Promissory Note
Following FDA filing acceptance on June 25, 2026, Spectral received the remaining US$1.0 million of the Tranche D advance from Vantive on July 28, 2026, completing the full US$2.0 million Tranche D funding under the senior secured promissory note. An earlier side letter agreement dated May 7, 2026 had allowed Vantive to advance the first US$1.0 million prior to the milestone being satisfied. The aggregate principal amount of promissory notes issued in 2025 and 2026 was $11,038,000. The company disclosed it continues to actively evaluate financing scenarios with a view to being fully funded beyond potential PMX commercialisation.





Please wait processing your request...